Lexaria Begins Dosing in Human Study Evaluating DehydraTECH-Semaglutide Formulations Against Wegovy

Lexaria Bioscience Corp. (Nasdaq: LEXX) announced that dosing has begun on schedule for Human Pilot Study #7 (GLP-1-H26-7), which evaluates two oral DehydraTECH-semaglutide compositions against Novo Nordisk's commercially available Wegovy tablets over a five-week duration. The study is fully funded from existing corporate resources.

Lexaria aims to preserve the superior safety and tolerability profiles observed in its previous GLP-1 studies, such as Human Study #4 (GLP-1-H24-4), while achieving pharmacokinetic performance that matches or exceeds the Wegovy tablet control. Previous single-dose studies with SNAC-inclusive DHT-sema, including Human Pilot Studies #1 and #2, demonstrated PK performance comparable to or better than Rybelsus and exhibited favorable safety profiles.

The results of this study are expected to be carefully reviewed by the pharmaceutical industry to evaluate potential commercial relationships focused on Lexaria's proprietary DehydraTECH technology. The study investigates three arms to assess safety, tolerability, and PK properties, comparing SNAC-inclusive DHT-sema formulations in tablet and capsule formats to commercially available Wegovy tablets. The study is conducted under fasted pre-dose conditions, similar to Novo's oral semaglutide administration criteria. The five-week dosing duration allows for achievement of steady-state concentration levels, where semaglutide blood levels reach equilibrium between drug input and elimination.

This study explores several new DehydraTECH enhancements not previously evaluated. First, an oral tablet DHT-sema composition is being used for the first time, as opposed to capsule compositions used in all previous DehydraTECH GLP-1 studies. Novo's Rybelsus and Wegovy oral semaglutide medications use specially formulated tablets designed to adhere to the stomach lining and release agents in a focal manner to optimize absorption. Lexaria has attempted to mimic and integrate certain physical properties of these SNAC-inclusive tablet delivery modalities into its DHT-sema tablets to follow industry standards and increase the likelihood of subsequent commercial pharmaceutical relationships. Second, both the Lexaria DHT-sema tablet and capsule test articles are formulated with SNAC, marking the first time these formulations are evaluated over a multi-dose, multi-week period in humans. Previous studies with SNAC, such as GLP-1-H24-1 and GLP-1-H24-2 conducted in 2024 and 2025, were limited to single-dose designs of shorter duration.

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology that improves the way drugs enter the bloodstream through oral delivery. The technology has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide.